Loading tape…Loading tape…
VRTX
VRTX
VRTX
Engineers Gate Manager LP has cut its stock holdings in Vertex Pharmaceuticals Incorporated ($VRTX), according to defenseworld.net. This portfolio adjustment comes as Vertex Pharmaceuticals commands a market capitalization of $138.61 billion, supported by a full-year revenue of $12.07 billion. Currently, the company trades at a PE ratio of 31.53, with a TTM EPS of 17.35 and a free cash flow yield of 2.74%.
Based on defenseworld.net3,678 Vertex Pharmaceuticals Incorporated $VRTX Shares Sold by Banque Pictet & Cie SA
Is Trending Stock Vertex Pharmaceuticals Incorporated (VRTX) a Buy Now?
Vertex Pharmaceuticals (VRTX) Rises Higher Than Market: Key Facts
Forget Cystic Fibrosis: Vertex's Next Growth Engine Could Be Hormone Disorders
Moderna vs. Vertex Pharmaceuticals: Which Healthcare Stock Is a Better Buy in 2026?
Better Healthcare ETF: VanEck's Biotech-Focused BBH vs. State Street's XPH Targeting Pharma
Revenue & Net Income (5Y)
EPS & Growth (5Y)
Free Cash Flow (5Y)
Capital Returns
Operating & Net Margin (5Y)
CapEx vs. Free Cash Flow (5Y)
Capital Allocation (5Y)
R&D and SG&A Intensity (5Y)
EBITDA (5Y)
Cost of Revenue (5Y)
Market Cap (5Y)
Ask Blinx with professional market data, charts beside chat, and your portfolio context.
Default quotes are Lang & Schwarz. NASDAQ is the delayed listing price. Charts stay daily. Not investment advice.